Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age: \>18 years~2. participants older than 18 years with either LAPC according to the American Joint Committee on Cancer (AJCC) criteria or isolated local recurrence with a maximum tumor diameter of 5 cm were considered eligible after pathologic confirmation~3. will receive IRE, gd Tcells~4. life expectancy: more than 3 months~5. ability to understand the study protocol and a willingness to sign a written informed consent document~6. adequate liver and renal function were required~7. intolerant or refused to chemotherapy or to chemotherapy~Exclusion Criteria:~1. patients with other kinds of cancer~2. history of coagulation disorders or anemia~3. heart disease and diabetes~4. history of epilepsy, severe coronary disease, a history of level 3 hypertension，myelosuppression, autoimmune disease~5. a performance status score of \>2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): In this group, the patients will receive IRE surgery to control the local tumor under CT .
- Group B (Type: EXPERIMENTAL): In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).